CLINICAL EVALUATION OF A NEW FORMULATION OF 99mTc-TRODAT-1 FOR SPECT IMAGING IN PARKINSON PATIENTS AND VOLUNTEER SUBJECTS

This study was conducted to evaluate the clinical usefulness of new developed kit of ^99mTc-TRODAT-1 to differentiate PD(Parkinson disease) from volunteer subjects. The 925-1111MBq (25-30 mCi) ^99mTc-TRODAT-1 samples were reconstituted by boiling water bath method. Fourteen subjects (women = 6, men = 8, age range 24 – 72, mean = 54.4) have been participated in this approach. The control group included (women = 2, men = 2, age = 25-70, mean = 54.75) and the other group included 10 PD patients (women = 4, men = 6, age = 42-72, mean = 54.1) the different stages of PD. Hoehin and Yahr Scale criteria was chosen for clinical evaluation of PD patients. Brain SPECT study has been performed using a single-headed gamma camera 3 hours post intravenous injection. Visual inspection of radiotracer uptake in the striatum and semi-quantitative analyses were performed. The radio-HPLC analysis indicated that the ^99mTc-TRODAT-1 samples were successfully prepared with a radiochemical purity over 90 %. Semi-quantitative analysis demonstrated that the negative relation between the striatal uptake and disease severity has been observed. The sensitivity and specificity of ^99mTc-TRODAT-1 brain imaging to detect PD were 100 % in our investigation. The SPECT brain imaging with a new developed kits of ^99mTc-TRODAT-1can be recommended as a useful modality for diagnosis and evaluation of the severity of PD in clinical practice.